Natural and induced human antibody response to cancer

Cancer Investigation

Volumn 18, Issue 5, 2000, Pages 480-489

  Lake, Douglas F ^a,b   Huynh, Wally C ^b   Hersh, Evan M ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN; MELANOMA VACCINE; MONOCLONAL ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CANCER; CANCER IMMUNOLOGY; CANCER PREVENTION; CARCINOGENESIS; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0034119422     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009032819     Document Type: Article

References (87)

1. Papac RJ: Spontaneous regression of cancer. Cancer Treat Rev 22:395-423, 1996.
2. Cole WH: Spontaneous regression of cancer. The metabolic triumph of the host? Ann NY Acad Sci 230:111-141, 1974.
3. Horn L, Horn H: An immunologic approach to the treatment of cancer? Lancet 2:466-469, 1971.
4. Bolande RP: The spontaneous regression of neuroblastoma: experimental evidence for a natural host immunity. Pathol Annu 26: 187-199, 1991.
5. Darnell RB, DeAngelis LM: Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341:21-22, 1993.
6. Zaheer W, Friedland ML, Cooper EB, et al.: Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy. Cancer Invest 11:306-309, 1993.
7. Winter SF, Sekio Y, Minna JD, et al.: Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 85:2012-2018, 1993.
8. Livingston PO, Zhang S, Lloyd KO: Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother 45:1-9, 1997.
9. Livingston PO, Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45:10-19, 1997.
10. Slinghuff CL, Seigler HF: Immunotherapy for malignant melanoma with a tumor cell vaccine. Ann Plast Surg 28:104-107, 1992.
11. Ahn SS, Irie RF, Weisenberger TH, et al.: Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response. Surgery 92:362-367, 1982.
12. Chee DO, Gupta RK, Morton DL: Presence of a carcinoma-associated antigen(s) in the spent chemically defined medium of a human colon carcinoma cell line. J Surg Oncol 13:45-51, 1980.
13. Applebaum J, Reynolds S, Knispel J, et al.: Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J Natl Cancer Inst 90:146-149, 1998.
14. Livingston PO, Natoli EJ, Calves MJ, et al.: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911-2915, 1987.
15. Livingston PO, Wong GYC, Adluri S, et al.: Improved survival in stage 111 melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994.
16. Houghton AN, Taormina MC, Ikeda H, et al.: Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci USA 77:4260-4264, 1980.
17. Sahin U, Tureci O, Schmitt H, et al.: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810-11813, 1995.
18. Yamaguchi H, Furukawa K, Fortunato SR, et al.: Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. Proc Natl Acad Sci USA 87:3333-3337, 1990.
19. Tai T, Paulson JC, Cahan LD, et al.: Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci USA 80:5392-5396, 1983.
20. Cahan LD, Irie RF, Singh R, et al.: Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 79:7629-7633, 1982.
21. Lloyd KO: Tumor antigens known to be immunogenic in man. In: Specific Immunotherapy of Cancer with Vaccines, edited by JC Bystryn, S Ferrone, P Livingston, New York, New York, Academy of Sciences, 1993.
22. Yagyu T, Monden T, Baba M, et al.: A cancer-reactive human monoclonal antibody derived from a colonic cancer patient treated with local immunotherapy. Jpn J Cancer Res 84:75-82, 1993.
23. Haspel MV, McCabe RP, Pomato N, et al.: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45:3951-3961, 1985.
24. Borup-Christensen P, Erb K, Ditzel H, et al.: Human-human hybridoma producing monoclonal antibodies against colorectal cancer-associated antigens. APMIS 98:674-684, 1990.
25. Mochizuki K, Kato M, Sato S, et al.: Characterization of a lung cancer-associated human monoclonal antibody HB4C5. Hum Antib Hybrid 2:116-123, 1991.
26. Ben-Mahrez K, Sorokine I, Thierry D, et al.: Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 46:35-38, 1990.
27. Winter SF, Minna JD, Johnson BE, et al.: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168-4174, 1992.
28. Bodurtha BJ, Chee DO, Laucius JF, et al.: Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res 35:189-193, 1975.
29. Morton DL, Malmgren RA, Holmes EC, et al.: Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233-240, 1968.
30. Muna NM, Marcus S, Smart C: Detection by immunofluorescence of antibodies specific for human malignant melanoma cells. Cancer 23:88-93, 1969.
31. Nagel GA, Piessens WF, Stilmant MM, et al.: Evidence for tumor-specific immunity in human melanoma. Eur J Cancer 7:41-47, 1971.
32. Nairn RC, Nind AP, Guli EP, et al.: Anti-tumor immunoreactivity in patients with malignant melanoma. Med J Australia 1:397-403, 1972.
33. Gupta RK, Morton DL: Suggestive evidence for in vivo binding of specific antitumor antibodies of human melanomas. Cancer Res 35:58-62, 1975.
34. Gupta RK, Theofilopoulos AN, Dixon FJ, et al.: Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. Cancer Immunol Immunother 6:211-221, 1979.
35. Kirkwood JM, Vlock DR: Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. Cancer Res 44:4177-4182, 1984.
36. Vlock DR, Kirkwood JM: Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes. J Clin Invest 76:849-854, 1985.
37. Vlock DR, DerSimonian R, Kirkwood JM: Prognostic role of antibody reactivity to melanoma. J Clin Invest 77:1116-1121, 1986.
38. Vlock DR, Scalise D, Meglin N, et al.: Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody. J Clin Invest 81:1746-1751, 1988.
39. Wong JH, Gupta RK, Morton DL: Serial determinations of melanoma tumor-associated antigen and antibody in patients with stage I melanoma. Arch Surg 121:1342-1345, 1986.
40. Gupta RK, Morton DL: Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 6:329-336, 1992.
41. Wong JH, Xu SH, Skinner KA, et al.: Prospective evaluation of the use of antigen-specific immune complexes in predicting the development of recurrent melanoma. Arch Surg 126:1450-1454, 1991.
42. Higuchi M, Gupta RK, Irie RF, et al.: Natural humoral immunity in patients with malignant disease. J Clin Lab Immunol 4:141-143, 1980.
43. Jones PC, Sze LL, Liu PY, et al.: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981.
44. Gupta RK, Leitch AM, Morton DL: Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients. Cancer Immunol Immunother 16:40-47, 1983.
45. Shiku H, Takahashi T, Oettgen HF, et al.: Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med 144:873-881, 1976.
46. Shiku H, Takahashi T, Resnick LA, et al.: Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristic J Exp Med 145:784-789, 1977.
47. Carey TE, Takahashi T, Resnick LA, et al.: Cell surface antigens of human malignant melanoma: I. Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 73:3278-3282, 1976.
48. Bystryn JC, Henn M, Li J, et al.: Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 52:5948-5953, 1992.
49. Carey TE, Lloyd KO, Takahashi T, et al.: AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization. Proc Natl Acad Sci USA 76:2898-2902, 1979.
50. Real FX, Mattes MJ, Houghton AN, et al.: Class 1 (unique) tumor antigens of human melanoma: Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med 160: 1219-1233, 1984.
51. Vlock DR, Aul DJ, Toporowicz A, et al.: Purification and partial characterization of a shed 66 kDa melanoma-associated antigen identified by autologous antibody. Biochim Biophys Acta 1080: 1-10, 1991.
52. Toporowicz A, Gersten DM, Hearing VJ, et al.: Cross-reactivity between murine melanoma antigen B700 and a human melanoma-associated antigen (M-66) recognized by autologous antibody: evidence suggesting shared epitopes. Biochim Biophys Acta 1182: 51-56, 1993.
53. Kummer U, Staerz U: Concepts of antibody-mediated cancer therapy. Cancer Invest 11:174-184, 1993.
54. Dillman RO: Antibodies and cytotoxic therapy. J Clin Oncol 12: 1497-1515, 1994.
55. Jurcic JG, Scheinberg DA, Houghton AN: Monoclonal antibody therapy of cancer. Cancer Chemother Biol Resp Mod 16:168-188, 1996.
56. Hamilton WB, Helling F, Lloyd KO, et al.: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 53:566-573, 1993.
57. Helling F, Livingston PO: Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin Mol Chem Neuropathol 21:299-309, 1994.
58. Ritter G, Boosfeld E, Adluri R, et al.: Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 48:379-385, 1991.
59. Yamaguchi H, Furukawa K, Fortunato SR, et al.: Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci USA 84:2416-2420, 1987.
60. Seigler HF, Wallack MK, Vervaert CE, et al.: Melanoma patient antibody responses to melanoma tumor-associated antigen defined by murine monoclonal antibodies. J Biol Resp Mod 8:37-52, 1989.
61. Hsueh EC, Gupta RK, Qi K, et al.: TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 3:364-370, 1997.
62. Hsueh EC, Famatiga E, Gupta RK, et al.: Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (Cancer Vax): correlation with survival. Ann Surg Oncol 5: 595-602, 1998.
63. Livingston PO, Takeyama H, Pollack MS, et al.: Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 31:567-575, 1983.
64. Livingston PO, Albino AP, Chung TJC, et al.: Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55:713-720, 1985.
65. Livingston PO, Kaelin K, Pinsky CM, et al.: The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer 56:2194-2200, 1985.
66. Kitamura K, Livingston PO, Fortunato SR, et al.: Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 92:2805-2809, 1995.
67. Chattopadhyay P, Starkey J, Morrow WJ, et al.: Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc Natl Acad Sci USA 89:2684-2688, 1992.
68. Chattopadhyay P, Sneed D, Rosenberg J, et al.: Monoclonal anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen: generation and characterization of anti-idiotype antibodies. Cancer Res 51:3183-3192, 1991.
69. Sen G, Chakraborty M, Foon KA, et al.: Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2 human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody Mel-1. J Immunother 21:75-83, 1998.
70. Baharav E, Merimsky O, Altomonte M, et al.: Anti-tyrosinase anti-bodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular- weight melanoma-associated antigen. Melanoma Res 5:337-343, 1995.
71. Lehmann PV, Sercarz EE, Forsthuber T, et al.: Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 14:203-208, 1993.
72. Foon KA, Sen G, Hutchins L, et al.: Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 4:1117-1124, 1998.
73. Levy R, Miller RA: Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monogr 10:61-68, 1990.
74. Hsu FJ, Caspar CB, Czerwinskt D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89:3129-3135, 1997.
75. Barbuto JAM, Verastegui EL, Hersh EM: The use of transformed T cell lines for clonal expansion of human B cells from peripheral blood, spleen and tumor-infiltrating lymphocytes. Hybridoma 12: 115-125, 1993.
76. Punt CJA, Barbuto JAM, Zhang H, et al.: Antitumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother 38:225-232, 1994.
77. Barbuto JAM, Grimes WJ, Hersh EM: Antibodies to tumor necrosis factor: a component of B cell immune responses with a role in tumor/host interaction. Cancer Immunol. Immunother 40:31-36, 1995.
78. Zhang H, Lake DF, Barbuto JAM, et al.: A human monoclonal antimelanoma single-chain Fv antibody derived from tumor-infiltrating lymphocytes. Cancer Res 55:3584-3591, 1995.
79. Cole SPC, Campling BG, Louwman IH, et al.: A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines. Cancer Res 44:2750-2753, 1984.
80. Watson DB, Burns GF, Mackay IR: In vitro growth of B lymphocytes infiltrating human melanoma tissue by transformation with EBV: Evidence for secretion of anti-melanoma antibodies by some transformed cells. J Immunol 130:2442-2447, 1983.
81. Yeilding NM, Gerstner C, Kirkwood JM. Analysis of two human monoclonal antibodies against melanoma. Int J Cancer 52:967-973, 1992.
82. Sahin U, Tureci O, Pfreundschuh M: Serological identification of human tumor antigens. Curr Opin Immunol 9:709-716, 1997.
83. Tureci O, U S, Pfreundschuh M: Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 342-349, 1997.
84. Tureci O, Schmitt H, Fadle N, et al.: Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem 272:6416-6422, 1997.
85. Chen YT, Scanlan MJ, Sahin U, et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous anti-body screening. Proc Natl Acad Sci USA 94:1914-1918, 1997.
86. Stockert E, Jager E, Chen YT, et al.: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-1354, 1998.
87. Old LJ: Cancer immunology: the search for specificity. G.H.A. Clowes Memorial Lecture. Cancer Res 41:361-375, 1981.